New York, July 07, 2015 -- Moody's Investors Service commented that the offer by Horizon Pharma plc ("Horizon") to purchase the outstanding equity of Depomed, Inc. (unrated) for $29.25 per share in stock has positive credit implications for Horizon if the offer is accepted. At this time there are no changes to Horizon's ratings or outlook. Horizon's subsidiary Horizon Pharma, Inc. is rated B2 (Corporate Family Rating) with a stable rating outlook.
Vollständigen Artikel bei Moodys lesen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.